AKTX

Akari Therapeutics plc ADS (AKTX)

About Akari Therapeutics plc ADS (AKTX)

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Boston, MA.

Details

Daily high

$1.22

Daily low

$1.15

Price at open

$1.20

52 Week High

$4.40

52 Week Low

$0.90

Market cap

14.4M

Dividend yield

0.00%

Volume

10,257

Avg. volume

70,324

P/E ratio

-.17

Akari Therapeutics plc ADS News